Welcome to our dedicated page for Equifax SEC filings (Ticker: EFX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Equifax’s credit files touch nearly every U.S. consumer, and that reach makes its SEC disclosures uniquely data-dense. The annual 10-K doesn’t just report revenue; it details cybersecurity investments, Equifax Cloud migration milestones, and how Workforce Solutions monetizes real-time income data. Whether you’re tracking credit-report volume, breach-related legal accruals, or global segment trends, this page gathers every document in one place and keeps it current.
Looking for the Equifax annual report 10-K simplified, the latest Equifax quarterly earnings report 10-Q filing, or an Equifax 8-K material events explained alert? They’re here alongside Equifax proxy statement executive compensation materials and each Equifax insider trading Form 4 transactions notice. Stock Titan’s AI reads the footnotes so you don’t have to, producing plain-English briefs that answer natural queries like “What are Equifax’s cyber spend trends?” or “How did Workforce Solutions margin move this quarter?” Our platform also streams Equifax Form 4 insider transactions real-time, highlighting officer buys and sells minutes after they hit EDGAR.
Use the summaries to compare fraud-loss reserves between periods, spot patterns in Equifax executive stock transactions Form 4, or dive into our Equifax earnings report filing analysis for revenue-per-file metrics. From risk factors to segment tables, you’ll find Equifax SEC filings explained simply; it’s all about understanding Equifax SEC documents with AI—faster, clearer, and always up to date.
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) filed seven Post-Effective Amendments on Form S-8 to deregister all unsold shares previously registered for issuance under its 2019 employee equity plans. The action follows the closing of its merger with Merck KGaA, Darmstadt, Germany on 1 July 2025, under which SpringWorks became a wholly owned subsidiary of Merck through EMD Holdings Merger Sub, Inc.
The amendments cover the following historical S-8 registrations:
- Reg. Nos. 333-234365, 333-237350, 333-253531, 333-262996, 333-270096, 333-277380 and 333-285076.
- In aggregate, these filings had registered tens of millions of common shares for the 2019 Stock Option & Incentive Plan, the Amended & Restated 2019 Equity Incentive Plan and the 2019 Employee Stock Purchase Plan.
Because the company is now private, SpringWorks has terminated all offerings under these plans. Consistent with undertakings in each registration statement, any securities that remained unsold as of the merger date are withdrawn from registration. The filing is signed on behalf of the company by Secretary Michael MacDougall and relies on Rule 478 of the Securities Act to omit additional signatures.
The amendments are largely administrative, signalling the end of SpringWorks’ status as an independent public issuer and the cessation of share issuance under its legacy equity compensation and ESPP programmes.
FAQ
What is the current stock price of Equifax (EFX)?
What is the market cap of Equifax (EFX)?
What is the core business of Equifax Inc?
How does Equifax generate revenue?
What industries rely on Equifax's data solutions?
How does Equifax maintain data security and regulatory compliance?
What role does technology play in Equifax's operations?
How does Equifax differentiate itself from other credit bureaus?
What is the significance of Equifax's global reach?
Why is workforce solutions an important part of Equifax's business?
